| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
DRUG METABOLISM/TRANSPORT |
From the Division of Clinical Pharmacology, Department of Medicine (Dr Urquhart, Dr Tirona, Dr Kim), and the Department of Physiology & Pharmacology (Dr Tirona), University of Western Ontario, London, Ontario, Canada.
Erratic or unpredictable response to drugs remains a challenge of modern drug therapy. An important determinant of such interindividual differences in drug response is variability in the expression of drug-metabolizing enzymes and/or transporters at sites of absorption and/or tissue distribution. Variable drug-metabolizing enzyme and transporter expression can result in unpredictable exposure and tissue distribution of drugs and may manifest as adverse effects or therapeutic failure. In the past decade, important new insights have been made relating to the regulatory mechanisms governing the expression of drug-metabolizing enzymes and transporters by ligand-activated nuclear receptors. Specifically, there is compelling evidence to demonstrate that PXR, CAR, FXR, LXR, VDR, HNF4
, and AhR form a battery of nuclear receptors that regulate the expression of many important drug-metabolizing enzyme and transporters. In this review, the authors focus on clinically important drug-metabolizing enzymes such as CYP3A4, CYP2B6, CYP2C9, CYP2C19, UGT1A1, SULT2A1, and glutathione S-transferases and their regulation by nuclear receptors. They also review the nuclear receptor-mediated regulation of drug transporters such as MDR1, MRP2, MRP4, BSEP, BCRP, NTCP, OATP1B3, and OATP1A2. Finally, they outline how the drug development process has been affected by the current understanding of the involvement of nuclear receptors in the regulation of drug disposition genes.
Key Words: Nuclear receptor • drug disposition • interindividual variability • drug-metabolizing enzyme • drug transporter
Address for reprints: Address for correspondence: Richard B. Kim, MD, Division of Clinical Pharmacology, London Health Sciences Centre—University Hospital, Room ALL-152, 339 Windermere Road, London, Ontario N6A 5A5, Canada; e-mail: richard.kim{at}lhsc.on.ca.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Tachibana, K. Yoshinari, T. Chikada, T. Toriyabe, K. Nagata, and Y. Yamazoe Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1 Drug Metab. Dispos., August 1, 2009; 37(8): 1604 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fan, S. Liu, Y. Du, J. Morrison, R. Shipman, and K. S. Pang Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1{alpha},25-Dihydroxyvitamin D3 and Vitamin D Analogs, in the Caco-2 Cell Monolayer J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 389 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Waxman and M. G. Holloway Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes Mol. Pharmacol., August 1, 2009; 76(2): 215 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gu, W. M. Tsark, D. A. Brown, S. Blanchard, T. W. Synold, and S. E. Kane A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging PNAS, March 31, 2009; 106(13): 5394 - 5399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-W. Li, G. K. Dinh, and J. D. Chen Preferential Physical and Functional Interaction of Pregnane X Receptor with the SMRT{alpha} Isoform Mol. Pharmacol., February 1, 2009; 75(2): 363 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Konno, S. Kodama, R. Moore, N. Kamiya, and M. Negishi Nuclear Xenobiotic Receptor Pregnane X Receptor Locks Corepressor Silencing Mediator for Retinoid and Thyroid Hormone Receptors (SMRT) onto the CYP24A1 Promoter to Attenuate Vitamin D3 Activation Mol. Pharmacol., February 1, 2009; 75(2): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. B. van Waterschoot, R. W. Rooswinkel, E. Wagenaar, C. M. M. van der Kruijssen, A. E. van Herwaarden, and A. H. Schinkel Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver FASEB J, January 1, 2009; 23(1): 224 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Kharasch, D. Mitchell, R. Coles, and R. Blanco Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1663 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ning, S. Dial, Y. Sun, J. Wang, J. Yang, and L. Guo Systematic and Simultaneous Gene Profiling of 84 Drug-Metabolizing Genes in Primary Human Hepatocytes J Biomol Screen, March 1, 2008; 13(3): 194 - 201. [Abstract] [PDF]
|
|
|
|
|
|
L. Svecova, R. Vrzal, L. Burysek, E. Anzenbacherova, L. Cerveny, J. Grim, F. Trejtnar, J. Kunes, M. Pour, F. Staud, et al. Azole Antimycotics Differentially Affect Rifampicin-Induced Pregnane X Receptor-Mediated CYP3A4 Gene Expression Drug Metab. Dispos., February 1, 2008; 36(2): 339 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Gow, L. W. Chinn, and D. L. Kroetz The Effects of ABCB1 3'-Untranslated Region Variants on mRNA Stability Drug Metab. Dispos., January 1, 2008; 36(1): 10 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moe, E. Grindflek, and O. Doran Expression of 3{beta}-hydroxysteroid dehydrogenase, cytochrome P450-c17, and sulfotransferase 2B1 proteins in liver and testis of pigs of two breeds: Relationship with adipose tissue androstenone concentration J Anim Sci, November 1, 2007; 85(11): 2924 - 2931. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
